海外の治験の状況「1」での検索結果
379件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A single-dose study of a new biologic drug for people with abnormal levels of insulin due to a genetic dysfunction
- Hypoglycaemia associated with congenital hyperinsulinism MedDRA version: 19.0 Level: LLT Classification code 10020644 Term: Hyperinsulinism NOS System Organ Class: 100000004861 MedDRA version: 19.0 Level: LLT Classification code 10022484 Term: Insulin hypoglycaemia System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- United Kingdom, United States
- 2015-08-24
Authorised
- A Phase III study to assess whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn's disease
- Crohn`s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2015-01-27
Authorised
- An Open-Label Extension Study to assess the long-term safety and effective of etrolizumab treatment for patients with moderately to severely active Crohn's disease
- Crohn`s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2015-01-27
Authorised
- A Controlled Study with an active treatment and a Placebo to Assess the Efficacy and Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha-1 Antitrypsin Deficiency
- Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency MedDRA version: 16.0 Level: LLT Classification code 10014563 Term: Emphysema pulmonary System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Argentina, Australia, Brazil, Canada, Denmark, Estonia, Finland, France, Ireland, New Zealand, Poland, Romania, Slovakia, Spain, Sweden, United States
- 2013-09-23
Authorised
- Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's disease
- Crohn's disease MedDRA version: 18.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Belgium, Canada, Central African Republic, Czech Republic, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Slovakia, South Africa, Spain, Switzerland, Tunisia, United Kingdom, United States
- 2013-01-14
Authorised
- A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients with Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
- Type 2 diabetes mellitus Chronic kidney disease stage 4 MedDRA version: 20.0 Level: LLT Classification code 10076411 Term: Chronic kidney disease stage 4 System Organ Class: 100000004857 MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United States
- 2017-07-25
Authorised
- Study to Assess Long term Safety and Efficacy of Current or Prior Treatment with Denosumab in Children/Young Adults with Osteogenesis Imperfecta
- Osteogenesis Imperfecta (OI) br>MedDRA version: 20.0 Level: PT Classification code 10031243 Term: Osteogenesis imperfecta System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
- Australia, Belgium, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom, United States
- 2018-05-10
Authorised
- A study of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in patients with lung cancer
- Non-Small Cell Lung Cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Canada, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Russian Federation, Serbia, Slovakia, South Africa, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2018-03-09
Authorised
- Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer
- Metastatic or Locally Advanced Solid Tumors and Cervical Cancer MedDRA version: 20.0 Level: LLT Classification code 10008231 Term: Cervical cancer recurrent System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- France, United States
- 2018-03-01
Authorised
- A phase III study of BI 201335 in combination with PegIFN/RBV in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment
- Chronic hepatitis C infection genotype 1 MedDRA version: 14.1 Level: PT Classification code 10019744 Term: Hepatitis C System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Austria, Belgium, Canada, France, Germany, Japan, Portugal, Romania, Spain, Switzerland, United Kingdom, United States
- 2011-04-12